Eltrombopag (Revolade®)

Assessment Status Assessment process complete
Drug Eltrombopag
Brand Revolade®
Indication For the treatment of chronic immune thrombocytopenic purpura (ITP)
Assessment Process
Full submission received from Applicant 30/07/2010
NCPE assessment completed 05/11/2010
NCPE assessment outcome The review group do not recommend the reimbursement of eltrombopag under the High Tech Drug scheme

Technical Summary

A new rapid review was commissioned by the HSE in December 2017
Rapid review commissioned 04/12/2017
Rapid review completed 16/04/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with currently available therapies.